Who are vildagliptin + acarbose's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): sitagliptin and acarbose.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/vildagliptin-acarbose.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-09 · How we verify

vildagliptin + acarbose — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

vildagliptin + acarbose (vildagliptin + acarbose) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: DPP-4 inhibitor + alpha-glucosidase inhibitor. Area: Diabetes.

phase 3 DPP-4 inhibitor + alpha-glucosidase inhibitor DPP-4, alpha-glucosidase Diabetes Small molecule Live · refreshed every 30 min

Target snapshot

vildagliptin + acarbose (vildagliptin + acarbose) — Radboud University Medical Center. Vildagliptin and acarbose work together to improve blood glucose control by enhancing insulin secretion and reducing carbohydrate absorption.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
vildagliptin + acarbose TARGET	vildagliptin + acarbose	Radboud University Medical Center	phase 3	DPP-4 inhibitor + alpha-glucosidase inhibitor	DPP-4, alpha-glucosidase
sitagliptin and acarbose	sitagliptin and acarbose	Nanjing First Hospital, Nanjing Medical University	marketed	DPP-4 inhibitor + alpha-glucosidase inhibitor combination	DPP-4 enzyme; alpha-glucosidase enzymes

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (DPP-4 inhibitor + alpha-glucosidase inhibitor class)

Radboud University Medical Center · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). vildagliptin + acarbose — Competitive Intelligence Brief. https://druglandscape.com/ci/vildagliptin-acarbose. Accessed 2026-06-09.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing